CML: Imatinib as effective in the elderly as in the young but warrants management of adverse eventsMay 5, 2021CML
CML-CP: Bosutinib outscores imatinib as a frontline treatment option in Asian subpopulationMay 5, 2021CML
Bosutinib is effective, relative safe in elderly CML patients resistant/intolerant to prior TKIsApril 6, 2021CML
Dasatinib/nivolumab combo safe but shows no meaningful activity in previously treated CMLApril 6, 2021CML
CML-CP: Sustained long-term high treatment-free remission rates following frontline nilotinib April 6, 2021CML
CML-CP: High red blood cell distribution width predicts poor outcomes in TKI-treated patients April 6, 2021CML
Hematology NewsPoor survival with COVID in patients who have had HSCTMarch 26, 2021CMLTransplantLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersALLDLBCLB Cell Lymphoma
Hematology NewsOmidubicel improves on umbilical cord blood transplantsMarch 22, 2021TransplantALLAMLCMLMyelodysplastic SyndromeB Cell LymphomaLeukemia, Myelodysplasia, Transplantation
Oncology PracticeDon’t delay: Cancer patients need both doses of COVID vaccineMarch 15, 2021Patient & Survivor CareAggressive LymphomasB Cell LymphomaT Cell LymphomasMultiple MyelomaMantle Cell LymphomaIndolent Lymphoma
